PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportsmyeloid leukemia accelerated phase
MeSH D015465 - myeloid leukemia accelerated phase
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D015464:Bcr-abl positive chronic myelogenous leukemia
$
Success rate
D015465: 
Myeloid leukemia accelerated phase
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
NovartisNilotinib Tasigna 2023-07-04 2007-10-29 $1,977 M Q2/20-Q2/23 
Clinical Trials
Historical Success Rate
Phase 1
84%
26/31
Phase 2
0%
0/41
Phase 3
50%
1/2
Approved: 1Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Novartis
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use